v3.22.2.2
Acquisitions and Divestitures - Consideration Paid For HRA Pharma (Details)
$ in Millions, € in Billions
Apr. 29, 2022
USD ($)
Apr. 29, 2022
EUR (€)
Oct. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Assets Acquired        
Operating lease assets     $ 209.8 $ 166.9
Goodwill     3,428.9 $ 2,999.4
HRA Pharma        
Business Acquisition [Line Items]        
Purchase Price $ 1,945.6 € 1.8    
Assets Acquired        
Cash and cash equivalents 44.2      
Accounts receivable 78.1      
Inventories 37.3   1.2  
Prepaid expenses and other current assets 16.7      
Property, plant and equipment, net 4.6      
Operating lease assets 9.7      
Goodwill 618.1   1.9  
Indefinite lived intangibles 1,388.1      
Deferred income taxes 10.3      
Other non-current assets 0.8      
Total assets 2,207.9      
Liabilities assumed        
Accounts payable 43.4   1.1  
Deferred income taxes 16.1      
Accrued customer programs 9.0      
Other accrued liabilities 13.7      
Accrued income taxes 0.4      
Deferred income taxes 169.0   1.1  
Other non-current liabilities 10.6   $ 0.7  
Total liabilities 262.2      
Noncontrolling interest 0.1      
Net Assets Acquired 1,945.6      
HRA Pharma | In-process research and development        
Assets Acquired        
Indefinite lived intangibles 63.3      
HRA Pharma | Trademarks, trade names, and brands        
Assets Acquired        
Definite-lived intangible assets, net 1,072.3      
HRA Pharma | Developed product technology        
Assets Acquired        
Definite-lived intangible assets, net 170.2      
HRA Pharma | Distribution networks        
Assets Acquired        
Definite-lived intangible assets, net $ 82.3